177 related articles for article (PubMed ID: 20729747)
1. Focus on renin-angiotensin system modulation and atrial fibrillation control after GISSI AF results.
Durin O; Pedrinazzi C; Inama G
J Cardiovasc Med (Hagerstown); 2010 Dec; 11(12):912-8. PubMed ID: 20729747
[TBL] [Abstract][Full Text] [Related]
2. [Non-antiarrhythmic pharmacological treatment of atrial fibrillation: focus on drugs acting on the renin-angiotensin system].
Durin O; Pedrinazzi C; Inama G
G Ital Cardiol (Rome); 2008 Oct; 9(10 Suppl 1):5S-10S. PubMed ID: 19195299
[TBL] [Abstract][Full Text] [Related]
3. The role of renin-angiotensin system blockade therapy in the prevention of atrial fibrillation: a meta-analysis of randomized controlled trials.
Zhang Y; Zhang P; Mu Y; Gao M; Wang JR; Wang Y; Su LQ; Hou YL
Clin Pharmacol Ther; 2010 Oct; 88(4):521-31. PubMed ID: 20811347
[TBL] [Abstract][Full Text] [Related]
4. [Unsatisfactory results of upstream therapy with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for the prevention of recurrent atrial fibrillation].
Disertori M; Zeni P; Quintarelli S; Bonmassari R
G Ital Cardiol (Rome); 2010 Nov; 11(11):829-34. PubMed ID: 21348320
[TBL] [Abstract][Full Text] [Related]
5. Role of renin-angiotensin system inhibitors in atrial fibrillation.
Disertori M; Latini R; Maggioni AP
J Cardiovasc Med (Hagerstown); 2011 May; 12(5):374; author reply 375. PubMed ID: 21451337
[No Abstract] [Full Text] [Related]
6. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers decrease the incidence of atrial fibrillation: a meta-analysis.
Huang G; Xu JB; Liu JX; He Y; Nie XL; Li Q; Hu YM; Zhao SQ; Wang M; Zhang WY; Liu XR; Wu T; Arkin A; Zhang TJ
Eur J Clin Invest; 2011 Jul; 41(7):719-33. PubMed ID: 21250983
[TBL] [Abstract][Full Text] [Related]
7. Clinical trials, the renin angiotensin system and atrial fibrillation.
Birnie DH; Gollob M; Healey JS
Curr Opin Cardiol; 2006 Jul; 21(4):368-75. PubMed ID: 16755207
[TBL] [Abstract][Full Text] [Related]
8. Atrial fibrillation and renin-angiotensin system.
Serra JL; Bendersky M
Ther Adv Cardiovasc Dis; 2008 Jun; 2(3):215-23. PubMed ID: 19124423
[TBL] [Abstract][Full Text] [Related]
9. The impact of suppressing the renin-angiotensin system on atrial fibrillation.
Kalus JS; Coleman CI; White CM
J Clin Pharmacol; 2006 Jan; 46(1):21-8. PubMed ID: 16397280
[TBL] [Abstract][Full Text] [Related]
10. Inefficiency of renin-angiotensin inhibitors in preventing atrial fibrillation in patients with a normal heart.
Fazio G; Pizzuto C; Sutera L; Guttilla D; Di Gesaro G; Cascio C; Novo G; Assennato P; Novo S
Minerva Cardioangiol; 2007 Jun; 55(3):311-5. PubMed ID: 17534249
[TBL] [Abstract][Full Text] [Related]
11. [Drugs for heart rate control and non-antiarrhythmic drugs in atrial fibrillation].
Chávez LL
Arch Cardiol Mex; 2007; 77 Suppl 2():S2-54-S2-58. PubMed ID: 17972380
[TBL] [Abstract][Full Text] [Related]
12. [Atrial fibrillation and renin-angiotensin system].
Yamashita T
Nihon Rinsho; 2007 Mar; 65(3):569-74. PubMed ID: 17354577
[TBL] [Abstract][Full Text] [Related]
13. Drug Insight: angiotensin-converting-enzyme inhibitors and atrial fibrillation--indications and contraindications.
Lévy S
Nat Clin Pract Cardiovasc Med; 2006 Apr; 3(4):220-5. PubMed ID: 16568131
[TBL] [Abstract][Full Text] [Related]
14. Drug therapy for atrial fibrillation.
Conway EL; Musco S; Kowey PR
Cardiol Clin; 2009 Feb; 27(1):109-23, ix. PubMed ID: 19111768
[TBL] [Abstract][Full Text] [Related]
15. Role of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and aldosterone antagonists in the prevention of atrial and ventricular arrhythmias.
Makkar KM; Sanoski CA; Spinler SA
Pharmacotherapy; 2009 Jan; 29(1):31-48. PubMed ID: 19113795
[TBL] [Abstract][Full Text] [Related]
16. Therapy with renin-angiotensin system blockers after pulmonary vein isolation in patients with atrial fibrillation: who is a responder?
Berkowitsch A; Neumann T; Kuniss M; Janin S; Wojcik M; Zaltsberg S; Mitrovic V; Pitschner HF
Pacing Clin Electrophysiol; 2010 Sep; 33(9):1101-11. PubMed ID: 20487340
[TBL] [Abstract][Full Text] [Related]
17. Rationale and design of the GISSI-Atrial Fibrillation Trial: a randomized, prospective, multicentre study on the use of valsartan, an angiotensin II AT1-receptor blocker, in the prevention of atrial fibrillation recurrence.
Disertori M; Latini R; Maggioni AP; Delise P; Di Pasquale G; Franzosi MG; Staszewsky L; Tognoni G;
J Cardiovasc Med (Hagerstown); 2006 Jan; 7(1):29-38. PubMed ID: 16645357
[TBL] [Abstract][Full Text] [Related]
18. Therapy with angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and statins: no effect on ablation outcome after ablation of atrial fibrillation.
Richter B; Derntl M; Marx M; Lercher P; Gössinger HD
Am Heart J; 2007 Jan; 153(1):113-9. PubMed ID: 17174648
[TBL] [Abstract][Full Text] [Related]
19. Atrial fibrillation: Blockade of the renin-angiotensin system in atrial fibrillation.
Kuzniatsova N; Shantsila E; Lip GY
Nat Rev Cardiol; 2010 Aug; 7(8):428-30. PubMed ID: 20657612
[No Abstract] [Full Text] [Related]
20. The effects of statins and renin-angiotensin system blockers on atrial fibrillation recurrence following antral pulmonary vein isolation.
Al Chekakie MO; Akar JG; Wang F; Al Muradi H; Wu J; Santucci P; Varma N; Wilber DJ
J Cardiovasc Electrophysiol; 2007 Sep; 18(9):942-6. PubMed ID: 17593228
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
